全球慢性难治性痛风市场：按地区和国家分析和预测（2025-2035 年）

推动慢性难治性痛风市场的主要成长要素之一是痛风及其相关风险因素的盛行率不断上升。

随着世界人口老化以及肥胖、高血压、METABOLIC INC.症候群等文明病的增加，包括慢性和难治性痛风在内的痛风发病率也在上升。患者数量的不断增长对更有效的治疗方法提出了更高的需求。此外，在现有降尿酸药物无效的难治性病例中，治疗选择有限，从而导致了生物製药和其他新治疗方法的开发。因此，患者对症状管理和预防长期关节损伤的需求正在推动市场成长。

另一方面，慢性难治性痛风市场的成长面临一些挑战，阻碍了其充分发挥潜力。主要挑战之一是使用聚乙二醇培格洛酶 (Krystexxa) 等生物製药治疗的成本高。对于患有严重且难治性痛风的患者来说，此类治疗方法至关重要，但费用昂贵，许多患者难以承受，尤其是低收入地区和保险有限的患者。另一个挑战是患者坚持长期治疗计画。许多痛风药物，尤其是生物製药，都是透过注射给药的，这可能会因副作用、给药复杂或缺乏病患教育而导致难以继续治疗。

此外，患者和医疗保健提供者对痛风管理缺乏认识和教育，导致误诊和延误治疗，进一步使难治性痛风的管理复杂化。此外，痛风常伴随的肾臟疾病等併发症使治疗计画变得复杂，并对有效治疗该疾病构成障碍。应对这些挑战对于改善患者治疗效果和更广泛地获得新治疗方法至关重要。

全球慢性难治性痛风市场正经历几个重要的新兴趋势。尤其值得注意的是人们对生物製药的兴趣日益浓厚。聚乙二醇重组尿酸酶（Krystexxa）等生物製药因其针对性的作用机制以及在治疗对常规治疗无反应的严重痛风病例方面具有很高的治疗潜力而受到关注。这些治疗方法包括单株抗体和酵素抑制剂，在显着降低尿酸水平、改善痛风石、防止关节损伤等方面表现出了显着的疗效，正在成为治疗慢性难治性痛风的核心。随着对更有效治疗的需求不断增加，生物製药有望引领市场，刺激下一代生物製药的进一步创新和研发。

本报告调查了全球慢性难治性痛风市场，并总结了主要趋势、市场影响因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章市场：产业展望

• 市场趋势
• 法律规范
• 流行病学分析
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 全球慢性难治性痛风市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

3. 全球慢性难治性痛风市场：竞争格局与公司概况

• 关键策略和发展
  • M&A
  • 协同效应活动
  • 业务扩展和资金筹措
  • 产品发布和核准
  • 其他活动
• 公司简介
  • Amgen Inc.
  • Cartesian Therapeutics, Inc.
  • Arthrosi Therapeutics, Inc.
  • Shanton Pharma Holdings Limited

第四章调查方法

Global Chronic Refractory Gout Market, Analysis and Forecast: 2025-2035

Chronic refractory gout (CRG) is a severe form of gout, a type of arthritis caused by the accumulation of uric acid crystals in the joints. Unlike typical gout, where symptoms respond to standard treatments like NSAIDs or uric acid-lowering drugs, chronic refractory gout is characterized by persistent symptoms that do not improve with conventional therapies. This form of gout often leads to ongoing inflammation, intense pain, and the development of tophi-large deposits of uric acid crystals that form under the skin and around joints.

The condition is challenging to manage, particularly when factors such as non-compliance, inadequate drug response, or co-existing conditions like kidney disease or obesity contribute to its persistence. Treatments for chronic refractory gout include biologic therapies such as pegloticase (Krystexxa), which helps lower uric acid levels in the blood, and other emerging drugs aimed at reducing flare-ups and improving quality of life. While the condition can cause significant joint damage if left untreated, the advent of new treatments offers hope for better management and symptom control in affected individuals.

One of the key drivers of the chronic refractory gout market is the rising prevalence of gout and associated risk factors. As the global population ages and lifestyle-related conditions such as obesity, hypertension, and metabolic syndrome become more prevalent, the incidence of gout, including its chronic and refractory forms, has been increasing. This growing patient population creates a significant demand for more effective treatments. Additionally, the limitations of existing therapies in managing refractory cases, which do not respond to traditional uric acid-lowering medications, have spurred the development of advanced biologics and other novel therapeutic options. This, in turn, drives market growth as patients seek better management options to control symptoms and prevent long-term joint damage.

Despite the growth of the chronic refractory gout market, several challenges persist that can hinder its full potential. One major challenge is the high cost of biologic therapies like pegloticase (Krystexxa), which are essential for treating severe, refractory cases of gout. These treatments can be prohibitively expensive, limiting access for many patients, especially in lower-income regions or for those without comprehensive insurance coverage. Another challenge is patient adherence to long-term treatment regimens. Many gout medications, particularly biologics, are administered via injections, which may lead to non-compliance due to side effects, administration complexity, or a lack of patient education.

Additionally, the lack of awareness and education about gout management among both patients and healthcare providers can contribute to misdiagnosis or delayed treatment, further complicating the management of refractory gout. Furthermore, co-morbid conditions such as kidney disease, which often accompany gout, complicate treatment plans and create additional barriers to achieving effective control of the disease. Addressing these challenges is essential for improving patient outcomes and ensuring broader access to emerging therapies in the chronic refractory gout market.

The global chronic refractory gout market is highly competitive, with several major companies actively involved, including Amgen Inc., Cartesian Therapeutics Inc., Arthrosi Therapeutics Inc., and Shanton Pharma Holdings Limited. These companies are at the forefront of developing and commercializing therapies aimed at addressing the unmet needs in managing chronic refractory gout, with a focus on innovative biologics, novel drug formulations, and targeted treatments to improve patient outcomes in this challenging condition.

The global chronic refractory gout market is experiencing several key emerging trends. One significant trend is the increased focus on biologic therapies. Biologics like pegloticase (Krystexxa) are gaining traction due to their targeted mechanism of action and ability to effectively treat severe, treatment-resistant cases of gout. These therapies, which include monoclonal antibodies and enzyme inhibitors, are becoming the cornerstone of chronic refractory gout treatment, offering substantial improvements in reducing uric acid levels, alleviating tophi, and preventing joint damage. As the demand for more effective treatments grows, biologics are expected to dominate the market, driving further innovation and research into next-generation biologic therapies.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Chronic Refractory Gout Market (Region), ($Million), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Chronic Refractory Gout Market, by Country
      • 2.1.3.1.1 U.S.
      • 2.1.3.1.2 Canada
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Chronic Refractory Gout Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Chronic Refractory Gout Market, by Country
      • 2.3.3.1.1 Japan

3. Global Chronic Refractory Gout Market: Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Amgen Inc.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Cartesian Therapeutics, Inc.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Arthrosi Therapeutics, Inc.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Shanton Pharma Holdings Limited
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Chronic Refractory Gout Market (by Region), $Million, 2024 and 2035
• Figure: Global Chronic Refractory Gout Market Clinical Trial Analysis
• Figure: Global Chronic Refractory Gout Market Key Trends, Analysis

List of Tables

• Table: Global Chronic Refractory Gout Market, Epidemiology Analysis,
• Table: Global Chronic Refractory Gout Market Dynamics, Impact Analysis
• Table: Global Chronic Refractory Gout Market (by Region), $Million, 2024-2035